Archives
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2018-07
- 
                
          Role of APPL in endosomal signaling2024-10-10  Role of APPL in endosomal signaling pathways Endosomes consist of distinct membrane subdomains within individual organelles and assist in the translation of extracellular stimuli via cytoplasmic transduction cascades to the nucleus [3], [74]. Endosomal abnormalities are associated with the pathogen 
- 
                
          br Difference between ACh and ER tests There are few2024-10-09  Difference between ACh and ER tests There are few reports concerning the provoked spasm between ER and ACh in the same patients [51], [52], [53]. Different mediators may have the potential of different coronary responses. In our experience, spasm provoked by intracoronary injection of ER is focal 
- 
                
          br AD and COX LOX pharmacology Early studies on the2024-10-09  AD and COX/5-LOX pharmacology Early studies on the role of cyclooxygenases in AD were inspired by epidemiological data suggesting that COX inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs) could be beneficial in AD patients (Lucca et al., 1994, McGeer et al., 1990). This line of re 
- 
                
          In the previous study we demonstrated the importance of2024-10-09  In the previous study, we demonstrated the importance of the mPFC postsynaptic 5-HT1A receptor in the sustained antidepressant effects, because a sustained antidepressant effect was obtained with intra-mPFC injection, but not systemic injection of 8-OH-DPAT, a 5-HT1A receptor agonist (Fukumoto et al 
- 
                
          eif2a The overall adjustment the non toxicity2024-10-09  The overall adjustment, the non-toxicity and the addiction-free treatment methods are the advantages of EA. EA treatment for depression has achieved great clinical effect in recent years (Dong et al., 2017). The clinical practice guideline of the American college of physicians (ACP) have pointed out 
- 
                
          Introduction Dementia is a common2024-10-09  Introduction Dementia is a common disease in the elderly, and a significant source of disability, healthcare spending, and long-term care admissions. There is evidence to suggest that testosterone plays a role in cognitive functioning, and lower serum levels correlate with higher amyloid deposits ( 
- 
                
          Matsuzaki et al attempted fertility therapy in2024-10-09  Matsuzaki et al. attempted fertility therapy in a 26-year-old female with secondary amenorrhea and 17OHD who was a Fmoc-Tyr(tBu)-OH heterozygote for delF53/54 and the missense mutation H373L, which has cycle supports this theory. Oocyte dysfunction with decreased granulosa cell activity might also 
- 
                
          Skeletal pain associated with bone fracture is another area2024-10-09  Skeletal pain associated with bone fracture is another area of critical need for a novel pain medication. NSAIDs and opiates are the two major therapies currently used to manage bone fracture pain. However, both of these therapies lead to significant unwanted side effects. Using the osteotomy model 
- 
                
          NOXA a member of the2024-10-09  NOXA, a member of the pro-apoptotic B-cell lymphoma 2 (BCL-2) family, plays a vital role in regulating mitochondrial or inherent apoptotic pathways [7,8]. NOXA binds to MCL-1 with high affinity and interacts with A1 (known as BCL2A1), resulting in BIM release to trigger subsequent apoptosis [9]. In 
- 
                
          Apelin induced G i activation has been demonstrated as2024-10-09  Apelin induced Gαi activation has been demonstrated as a benefiting effect on cardiac contractility [12], [38], [39], and a vasodilator activity that protects against angiotensin-II-induced cardiovascular fibrosis and atheroma [40], [41]. In contrast, stretch causes hypertrophy through diminishing G 
- 
                
          Acknowledgments br Introduction Pulmonary fibrosis2024-10-09  Acknowledgments Introduction Pulmonary fibrosis (PF) is a chronic, fibrosing interstitial pneumonia and a crushing disease that occurs as a result of a variety of lung injuries, including auto-immune, tuberculosis and traumatic insult [1], [2]. PF is characterized by the accumulation of extracel 
- 
                
          AR Vs are truncated AR proteins lacking the AR2024-10-09  AR-Vs are truncated AR proteins lacking the AR ligand-binding domain (AR-LBD) [6]. While AR-Vs have frequently been detected in CRPC, their expression and functional role in benign prostate tissues and primary prostate cancers is not readily apparent. Structural rearrangements in the AR gene and alt 
- 
                
          AHR mediated MMP upregulation has2024-10-08  AHR-mediated MMP1 upregulation has been shown in response to tobacco smoke [32]. Tobacco smoke contains various AHR ligands such as benzo[a]pyrene. Both benzo[a]pyrene [15] and FICZ [13] are high-affinity ligands for AHR and upregulate CYP1A1 and CYP1B1. FICZ is rapidly degraded by CYP1A1 [20], [33] 
- 
                
          The present study showed for2024-10-08  The present study showed, for the first time, that hirsutine, hirsuteine, rhynchophylline, isorhynchophylline, corynoxeine, and isocorynoxeine in yokukansan can inhibit the 5-HT3 receptor current. These data indicate that part of the effect of yokukansan against the behavioral and psychological symp 
- 
                
          In the late s Solvay Pharmaceuticals discontinued2024-10-08  In the late ‘90s, Solvay Pharmaceuticals discontinued the Phase 2 development of a promising potent and highly selective A1AR antagonist based on the pyrrolopyrimidine scaffold, SLV320 [43] (2, Chart 1, also named derenofylline; Ki hA1AR = 1 nM), for the treatment of acute heart failure [24]. In the 
14422 records 71/962 page Previous Next First page 上5页 7172737475 下5页 Last page